Introduction
Epithelial ovarian cancers (EOCs) represent .90% of malignant ovarian tumours. EOCs are usually diagnosed at a late stage (Stage III/IV) when the 5 years survival rates are poor ($30%). It is now well established that EOC histotypes have distinct molecular features and clinical characteristics (1); however, the molecular mechanisms underlying early-stage disease development and disease heterogeneity remain poorly understood. A more detailed understanding of the genesis of EOCs may lead to the identification of novel biomarkers that can be used for the detection of disease at its earliest most treatable stages and/or novel targets for therapeutic intervention.
EOCs are characterized by histological and molecular heterogeneity, and somatic genetic alterations occur in a subtype-specific manner. High-grade serous tumours are characterized by defects in DNA repair (often due to alterations in the BRCA1/2 and p53 pathways) and genetic aberrations in PIK3CA, KRAS and p16 (2-4). KRAS or BRAF mutations are found in two-thirds of low-grade serous/low malignant potential (LMP) EOCs (5) . Clear cell and endometrioid tumours frequently harbour loss of PTEN or mismatch repair gene function (6) ; and up to 50% of mucinous tumours have also been found to harbour KRAS mutations (7) . Finally, overexpression or amplification of the CMYC oncogene occurs in up to 65% of EOCs and in all of the four major subtypes of disease (serous, endometrioid, mucinous and clear cell) and is more common in malignant tumours (8, 9) .
One of the major impediments to understanding EOC development is the challenge of developing in vitro or in vivo models that accurately reflect the complex disease aetiology. Previous in vitro approaches to modelling normal ovarian epithelial cell transformation have used the SV40T antigen, with or without overexpression of the catalytic subunit of telomerase human telomerase reverse transcriptase (hTERT), in combination with a overexpression/activation of oncogenes known to be involved in EOC (e.g. KRAS, HRAS and c-erbB-2) (10,11). Transformed cells have been shown to exhibit a neoplastic phenotype both in vitro and in vivo. In a more recent study, normal primary ovarian epithelial (POE) cells immortalized by hTERT, cyclinD1 and cdk4 were shown to form tumours in vivo when they expressed mutant KRAS and a dominantnegative p53 construct (12) . However, the extent to which such models reflect the molecular heterogeneity of EOCs has yet to be established.
Gene expression microarray profiling of ovarian tumour specimens has shown that the different histological subtypes of EOC are distinguishable by their molecular profiles (13) . Gene expression profiles of ovarian tumours have been shown to correlate with tumour stage and grade, BRCA1/2 mutation status, chemotherapeutic response, immune cell infiltration and patient survival (14) (15) (16) (17) . However, the scarcity of early tumour specimens means that there are limited opportunities to study gene expression changes occurring early in EOC development (18, 19) .
In the current study, we have created a three-dimensional (3D) in vitro model of POE cell transformation using defined genetic elements known to be involved in EOC development. 3D culture models of normal and neoplastic cells have been shown to restore functional differentiation of the tissue in vivo in a manner that cannot be achieved in conventional 2D monolayer cultures (20) (21) (22) . We thus employed a 3D cell culture approach to more accurately model the architecture and complex cell-cell interactions of early avascular tumour nodules, hypothesizing that such features play a key role during early neoplastic progression. POE cells were engineered to overexpress the CMYC oncogene and mutant variants of either KRAS or BRAF. In this way, we aimed to model molecular and histotype heterogeneity of ovarian cancers. Candidate genes and gene expression signatures identified from the molecular analysis of this model were validated in EOC cell lines and using publicly available molecular and clinical data from the analysis of both low-grade/earlystage and high-grade/late-stage primary EOCs. Our results demonstrate that this in vitro model of POE transformation shares many molecular features with primary tumours, suggesting it is a robust model of serous ovarian cancer development.
years of age and undergoing total abdominal hysterectomy plus bilateral salpingooophorectomy for endometrioid endometrial cancer (stage 1) plus cervical clear cell carcinoma. Patient 19 was 39 years of age and undergoing total abdominal hysterectomy with a diagnosis of cervical carcinoma. Ovaries were confirmed as free of disease by the operating surgeon and a gynaecological pathologist (E.B.) before use in this study. Tissues were collected with the approval of the UCLH NHS Trust Clinical Ethics Committee and all cell lines were grown in normal ovarian surface epithelial-complete medium (24 CMYC and derivative cell lines were grown with 3 lg/ml blasticidin-S-hydrochloride. Clones expressing KRAS G12V were selected with 125 lg/ml to 1 mg/ml G418, whereas clones-expressing BRAF V600E were selected with 400 ng/ml puromycin (all Sigma, St. Louis, MO).
Immunoblotting, quantitative real-time polymerase chain reaction and restriction fragment length polymorphism polymerase chain reaction analysis Cells were starved for 48 h by culture in 0.1% fetal bovine serum. Immunoblotting of total cellular extracts (10 lg) was performed with anti-mitogen-activated protein kinase (MAPK) and anti-active-MAPK antibodies (1:5000; Promega, Madison, WI). For detection of the KRAS restriction fragment length polymorphism, cDNA preparations were subjected to polymerase chain reaction (PCR) amplification using KRAS-F primer: 5#-GACTGAATATAAACTTGTGG-TAGTTGGACCT-3# and KRAS-R primer 5#-TCCTCTTGACCTGCTGTGT-CG-3#, with an annealing temperature of 58°C. 1 lg purified PCR product was then digested with BstN1 overnight at 60°C. For detecting CMYC overexpression, RNA extracts were reverse transcribed using MMLV reverse polymerase (Promega) and the CMYC transcript abundance analysed using semiquantitative real-time PCR performed with Taqman probes (Applied Biosystems, Carlsbad, CA). 18S rRNA was used as an internal control and data were analysed using the DDCt method.
In vitro transformation assays Immunofluorescent staining was performed using standard protocols. Cells were stained with an anti-cytokeratin-7 primary antibody (1:1000, clone LP5K; Cancer Research UK, London, UK) and an Alexa-Flour-488 conjugated secondary antibody (1:2500 dilution; Invitrogen, Carlsbad, CA). Cells were counterstained with 1% wt/vol Evans Blue/H 2 O and nuclei labelled with DAPI (100 ng/ml; Sigma). Cells were viewed with an Olympus BX64 fluorescence microscope and images captured using Cytovision Genus 3.6 software. For anchorage-independent growth assays 10 2 cells were resuspended in complete medium containing 0.3% Noble Agar (Sigma) on top of a base layer of complete medium containing 0.6% Noble Agar. After 4 weeks, cells were fixed with methanol and stained with 1% p-iodonitrotetrazolium violet (Sigma). Colony forming efficiencies (CFE %) were calculated using the following formula:
To test invasiveness, flourimetric invasion assays (ECM554, Millipore, Billerica, MA) were used. Briefly, cells were washed in serum-free medium, a cell suspension made at 0.5 Â 10 6 cells/ml. Two hundred and fifty microlitres cell suspension was then applied to rehydrated invasion membranes. 10% serum in serum-free medium was added to the lower chamber as chemoattractant and the plates incubated for 24 h at 37°C before detection, according to manufacturer's instructions. Plates were read on a Varioskan platereader (Thermo Scientific, Waltham, MA).
3D culture
For 3D cultures, tissue culture plastics were coated twice with a 1.5% solution of poly-2-hydroxyethyl methacrylate (polyHEMA), prepared in 95% ethanol (both Sigma). 3D cultures were refed twice weekly, before spheroids were harvested, fixed in neutral-buffered formalin (VWR, Radnor, PA) and processed into paraffin. Immunohistochemistry of 3D cultures was performed using standard protocols at the UCL Advanced Diagnostics Laboratory. For 3D proliferation assays, cells were plated into polyHEMA coated 48-well plates and incubated with 10% Alamar Blue (Invitrogen). Flourimentric emissions were read at regular intervals on a Varioskan platereader (Thermo).
RNA preparation and gene expression microarray analysis RNA was extracted from triplicate 14 days spheroid cultures using the RNeasy Mini Kit (QIAGEN Venlo, Netherlands), with on-column DNase I digestion. Spheroids were washed in phosphate-buffered saline, resuspended in QIAGEN lysis buffer then passed through a 22 gauge needle 10 times. RNA samples were quality checked using the 2100 BioAnalyser (Agilent, Santa Clara, CA). RNA was amplified and labelled using the Ambion Illumina TotalPrep RNA Amplification kit (Ambion, Austin, TX). Briefly, 500 ng RNA was reverse transcribed to cDNA, then biotinylated nucleoside triphosphates were incorporated during in vitro transcription overnight to generate labelled cRNA. Hybridization, staining and scanning were carried out according to the Illumina Whole-Genome Gene Expression Direct Hybridization Protocol. 750 ng of biotin-labelled cRNA was hybridized to the Illumina Human HT-12 Expression Beadchip (Illumina, San Diego, CA). Chips were incubated at 58°C for 16-20 h. Following hybridization, chips were washed and then stained with Streptavidin-Cy3 dye. Chips were scanned in the Illumina iScan scanner and data produced via the Illumina GenomeStudio v1.0 software.
Data analysis
Analysis of microarray data was performed using the statistical language R and extensions taken from Bioconductor. Unless stated, all analyses were performed using default functions from R. Basic data processing including background subtraction, variance stabilization transformation and robust spline normalization were performed with the 'lumi' package (25) . Differentially expressed probes were detected using the 'limma' package with Benjamini-Hochberg correction for multiple testing (26) . Illumina probes were mapped to genes firstly by mapping them to Refseq IDs through the lumi annotation packages before using Ensembl to map these to Ensembl gene IDs. Genes were mapped to Gene Ontology (GO) terms through Ensembl and the Bioconductor package 'GO.db'. Enriched terms were detected using Fisher's exact tests in R with BenjaminiHochberg correction for multiple testing. IOE11 and 19 samples were analysed independently of each other before being combined for final results.
Previously published datasets used in this study were downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). The data of Yoshihara et al. (27) were downloaded as processed data from GEO accession GSE12470 and mapped to Ensembl Gene IDs using gene symbols. The data of Tothill et al. and Anglesio et al. (13, 17) were both downloaded as raw files from GEO (GSE9899 and GSE12172) and processed using the RMA algorithm (Bioconductor 'affy' package) and updated annotations with probes mapped to Ensembl genes (28) .
Gene expression signatures were generated as the median log2 ratio of each gene that significantly changed in both IOE11 and 19 cells. These were then related to tumours by calculating the Spearman's correlation between tumour data that had been scaled to Z-scores and the signature. Tumours with a high correlation value therefore had high expression of genes up-regulated in the model and low expression of genes down-regulated in the model relative to other tumours. To define high-and low-correlating samples in the Tothill dataset, the 20% of tumours with the highest and lowest correlations with each signature were then selected. Survival analyses were performed using the R 'survival' package.
Candidate gene expression validation EOC cell lines and growth media are listed in supplementary Table 2 , available at Carcinogenesis Online. POE cells were collected during total abdominal/ laparoscopic hysterectomy procedures at University College Hospital, London. Ovaries were confirmed as free of disease by a gynaecological pathologist. POE cells harvested from ovaries by gentle brushing with a cytobrush and cultured in normal ovarian surface epithelial-complete medium (21, 26) . Cell lines were grown to 80% confluency and RNA extracted using the QIAGEN RNeasy kit. RNA was then reverse transcribed to cDNA using random hexamers and the MMLV reverse transcriptase enzyme (both Promega). Semiquantitative real-time PCR was performed using the following probes: CTGF, Hs01026926_g1; RGS4, Hs00194501_m1; THBS1, Hs00962914_m1, GAPDH, 4310884E; b-actin, 4310881E; ATP5B: hs00969567_g1 and PSMA6, hs00853240_sH. Samples were analysed on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems) and analysed using the ddCt relative quantification method. Expression for each candidate gene was normalized against GAPDH, b-actin, PSMA6 or ATP5B. For the analysis of expression in tumours, data were downloaded from The Cancer Genome Atlas (TGCA) Pilot Project, established by the NCI and NHGRI. Information about the TGCA network can be found at http://cancergenome.nih.gov.
Results
Stepwise neoplastic transformation of ovarian epithelial cells after hTERT, CMYC, KRAS G12V /BRAF V600E expression To model neoplastic transformation and phenotypic heterogeneity of EOC, we first immortalized primary ovarian epithelial (POE) cells by overexpressing the catalytic subunit of hTERT. Two immortalized ovarian epithelial (IOE) cell lines were established from different individuals (IOE11 and IOE19); both cell lines expressed hTERT and had an extended lifespan relative to POE cells ( Figure 1A ) Lawrenson (23) . Subsequently, a full-length CMYC cDNA was introduced into both IOE cell lines by retroviral infection to generate IOE11 CMYC and IOE19 CMYC lines stably overexpressing CMYC. The expression of CMYC in IOE cells was confirmed by quantitative PCR ( Figure 1B) (23) . IOE11 CMYC and IOE19 CMYC cells were then transfected with full-length mutant copies of either KRAS or BRAF oncogenes [KRAS G12V and BRAF V600E , the most commonly occurring mutations found in EOC specimens (27) ] to create IOE CMYC.KRAS and IOE CMYC.BRAF cell line pairs. Expression of KRAS G12V in IOE CMYC.K-RAS cells was confirmed using a restriction enzyme digestion assay that selectively detects the G12V mutation ( Figure 1C) . Expression of the BRAF V600E in IOE CMYC.BRAF cells was confirmed by showing activation of the MAPK pathway in cell lines stably expressing BRAF V600E . MAPK signalling was also enhanced in cell lines expressing KRAS G12V , although levels of phosphorylated ERK were lower than in cell lines expressing BRAF V600E ( Figure 1D) 
. This is also consistent with primary EOCs, in which commitment to an epithelial phenotype is associated with progression to malignancy. IOE CMYC.KRAS and IOE CMYC.BRAF cells were also significantly more invasive and showed increased rates of anchorage-independent growth compared with IOE CMYC cells, suggesting the phenotypic effects of the oncogenes were additive ( Figure 1E and F) . Expression of BRAF V600E (but not KRAS G12V ) alone tended to induce a senescent phenotype, and a small but significant increase in anchorage-independent growth rates was observed in IOE19 expressing KRAS G12V alone (data not shown).
In vitro 3D modelling of IOE cell transformation We established 3D spheroid models of IOE, IOE CMYC , IOE CMYC.K-RAS and IOE CMYC.BRAF cell lines by culturing cells on polyHEMAcoated tissue culture plastics for 14 days. IOE cells underwent growth arrest when cultured in 3D, whereas IOE CMYC and IOE CMYC.BRAF cell lines were highly proliferative in 3D growth assays ( Figure 1G ). However, IOE CMYC.KRAS cells were significantly less proliferative than IOE CMYC and IOE CMYC.BRAF cells. Formalin-fixed paraffinembedded sections of 3D spheroids were stained by haematoxylin and eosin (H&E). IOE cells had a spindled morphology, produced foci of matrix material and were characteristic of the 3D cultures of primary ovarian epithelial cells (i.e. prior to hTERT immortalization). In haematoxylin and eosin-stained sections IOE CMYC/KRAS/BRAF spheroids, cells were often pleiomorphic, with an ill-defined and eosinophilic cytoplasm. Transformed cells frequently contained pleiomorphic nuclei and prominent nucleoli. Syncytial cell structures and frequent mitoses were present, which are indicative of rapid uncontrolled proliferation. The centre of the larger IOE CMYC/KRAS/BRAF spheroids contained foci of apoptotic and/or necrotic cells. Immunohistochemical staining of spheroid sections for the proliferative marker MIB1 and the tumour-associated marker Wilms tumour 1 , confirmed the neoplastic characteristics of IOE CMYC/KRAS/BRAF cells compared with the IOE cells ( Figure 1H ).
Characterizing molecular genetic profiles in the IOE transformation model The Illumina Human HT-12 Expression BeadChip gene expression microarray platform was used to profile the expression of 27 455 genes in IOE, IOE CMYC , IOE CMYC.KRAS and IOE CMYC.BRAF cell line pairs after 3D spheroid culturing. One-way analysis of variance tests identified 6183 genes differentially expressed between IOE11 cells and IOE11 CMYC/KRAS/BRAF cells and 4959 genes differentially expressed between IOE19 cells and IOE19 CMYC/KRAS/BRAF cells (adjusted P , 0.01). Of these, 3734 differentially expressed genes were common to both IOE11 and IOE19 cell lines (Figure 2A) . We performed an analysis of GO Biological Process term enrichment. There were 178 GO terms enriched in IOE11 cells expressing CMYC/KRAS/BRAF and 177 GO terms enriched in IOE19 cells; 146 terms were common to the two cell lines (Benjamini Hochberg adjusted P , 0.05) ( Figure 2B ). The GO-term enrichments in IOE11 and IOE19 cells were highly correlated (R 2 5 0.8084, Spearman's R, a 5 0.05) ( Figure 2C ), suggesting a high degree of concordance in the molecular changes induced by oncogenes in each cell line, which was confirmed by unsupervised hierarchical cluster analysis ( Figure 2D ).
We next analysed gene expression profiles to identify the molecular changes that were associated with CMYC, KRAS G12V and BRAF V600E expression in IOE cells based on biological function (using a falsediscovery rate of $1%). Comparing IOE and IOE CMYC cells, several of the GO terms enriched were associated with cell growth and proliferation (Table IA) (Table IB) and NF-kappaB signalling (Fisher's exact test, adjusted P 5 0.030). In IOE CMYC.BRAF cells, the enriched genes were involved in metabolic processes and DNA repair (Fisher's exact test, adjusted P 5 0.043) (Table IC) . Finally, in a pairwise comparison of IOE CMYC.-BRAF and IOE CMYC.KRAS profiles, 33 and 39% of the enriched GO terms were involved in developmental processes and regulation of apoptosis, respectively, (Fisher's exact test, adjusted P , 0.05; Table ID) .
Genes and expression signatures associated with ovarian cancer progression and patient survival In order to validate this genetic model of EOC development, we compared the molecular features of the model with those of primary ovarian tumours and EOC cell lines. We identified several genes that were differentially expressed between IOE CMYC , IOE CMYC.BRAF or IOE CMYC.KRAS cells compared with IOE cell lines, suggesting that they may be biologically significant in the initiation and early-stage EOC development (supplementary Table 1 (H) Formalin-fixed paraffin-embedded spheroid cultures were stained for MIB1, Wilms tumour 1 (WT1) and cytokeratin-7 (Ck7, green) expression by immunohistochemistry. Nuclear expression of MIB1, a proliferation marker, was up-regulated in association with oncogene expression. Ck7 expression was increased in transformed cell lines, reflecting the commitment to epithelial differentiation observed in EOCs. WT1 is a marker commonly expressed in ovarian tumours, we observed nuclear WT1 staining in IOE CMYC and IOE CMYC.BRAF spheroids (arrow). Brown colour denotes positive staining, haematoxylin (blue) was used as a counterstain. The data described in this figure were similar for both cell lines of each pair, although the observed phenotypic heterogeneity between the two cell line models suggests that genetic background can significantly modulate neoplastic progression.
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Carcinogenesis Online). These included regulator of G-protein signalling 4 (RGS4, adjusted P 5 1.44 Â 10 À11 in IOE11 and 4.50 Â 10 À13 in IOE19); connective tissue growth factor (CTGF, adjusted P 5 1.06 Â 10 À10 in IOE11 and 1.98 Â 10 À15 in IOE19) and thrombospondin-1 (THBS1; adjusted P 5 9.22 Â 10 À11 in IOE11 and 1.47 Â 10 À14 in IOE19) ( Figure 3A -C and supplementary Figure 1 is available at Carcinogenesis Online). The data (summarized in Figure 3) suggest that all three genes are down-regulated (i.e. have a tumour suppressor function) during neoplastic development. To validate these genes, we compared their expression between 40 early passage cultures of normal primary ovarian epithelial cell lines and 38 EOC cell lines ( Figure 3) ; all three genes were significantly down-regulated in EOC cell lines, particularly RGS4 (Wilcoxon rank-sum test, P 5 1.6 Â 10 À7 and P 5 2.2 Â 10 À7 normalized to GAPDH and b-actin endogenous controls, respectively). Gene expression data generated from the analysis of 216 high-grade serous, primary EOCs by The Cancer Genome Atlas Project (http:// cancergenome.nih.gov) also suggested these genes are frequently down-regulated during EOC development (Figure 3) . Finally, earlystage ovarian tumours showed significant down-regulation of these three genes compared with normal controls (supplementary Figure 2 is available at Carcinogenesis Online).
From the expression profiles of IOE CMYC , IOE CMYC.BRAF and IOE CMYC.KRAS , we derived CMYC-, KRAS G12V -and BRAF V600E -induced gene signatures, which comprised 1351, 515 and 496 genes, respectively (adjusted P 5 0.001, 0.1% false-discovery rate) ( Figure 4A) . We compared these signatures to expression profiles from 30 LMP serous ovarian tumours and 60 invasive serous ovarian tumours (17) . The CMYC signature showed a significantly greater correlation with the expression profiles from invasive tumours compared with LMP tumours (P 5 0.018) ( Figure 4B ). There was a similar trend for the KRAS signature, although this was not significant (P 5 0.26). There was no correlation between the BRAF signature and signatures for LMP or invasive tumours (P 5 1). This was confirmed in a second set of expression profiles from 285 ovarian tumours (16) in which the CMYC signature was associated with increased tumour grade (supplementary Figure 3 is available at Carcinogenesis Online).
Finally, we investigated whether oncogene signatures derived from our model can predict clinical outcome (survival) in patients diagnosed with EOC. Oncogene-signatures were compared with the expression profiles of 285 tumours from patients diagnosed with serous or endometrioid ovarian, peritoneal or fallopian tube cancers (13) . We found no difference in patient survival associated with expression profiles of tumours compared with CMYC or KRAS signatures [P 5 0.1025 and P 5 0.9874; Figure 4C , (i) and (ii)]. However, tumour profiles that positively correlated with the BRAF signature were associated with a significant improvement in relapse-free survival, compared with tumour profiles that negatively correlate to the BRAF signature (P 5 0.003) [ Figure 4C , (iii)].
Discussion
Identifying biomarkers or screening methodologies that indicate the early stages of cancer development may provide targets for clinical intervention that can substantially reduce disease mortality. Examples Regulation of developmental process 0.0087
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include the introduction of PAP smear testing to identify the earliest lesions for cervical carcinomas, PSA testing for prostate cancer and MRI screening for breast cancer (33) (34) (35) . Most EOCs are diagnosed at an advanced stage when prognosis is poor ($30% survival rates for stage III/IV disease) largely because disease symptoms are mild or non-specific to EOC (34) . However, 5 years survival rates in women diagnosed with stage 1 disease can exceed 85% (36) . The aim of this study was to develop an in vitro genetic model that mimics the early stage development of EOCs from normal ovarian epithelial cells, which can be used to identify novel biomarkers of early stage disease. We first immortalized POE cells using hTERT (IOE cells) and then transformed IOE cells using overexpression of CMYC plus expression of constitutively active KRAS or BRAF to recapitulate the somatic genetic aberrations that have been found in primary serous ovarian cancers (the most common subtype of EOCs). Phenotypic analysis suggested that the sequential addition of oncogenic elements promoted neoplastic progression at each stage to generate a model of stepwise tumour development similar to the classical model of clonal evolution proposed by Vogelstein et al. for colorectal cancer (37) . The expression of Wilms tumour 1 in our 3D model provides evidence that it reflects early-stage serous ovarian cancer; staining for Wilms tumour 1 is used clinically to diagnose serous ovarian tumours and was markedly increased in the cell lines engineered to express CMYC ± BRAF V600E (1,38). Our model is also one of divergent evolution and both the genetic and phenotypic heterogeneity that characterizes primary EOC specimens. The KRAS and BRAF oncogenes both function in the MAPK pathway, and data suggest that mutation of one of these genes, but not both, is required for EOC development (39) . However, whereas many studies have found KRAS mutations to be relatively common in all histological subtypes of EOCs, BRAF mutations are limited to the low-grade serous subtype (3, 5, 39) . In our model, we found phenotypic and molecular heterogeneity depending on whether KRAS or BRAF were activated. For example, expression of BRAF V600E in IOE CMYC cells was associated with increased MAPK signalling and proliferation in 3D, relative to expression of KRAS G12V .
Previous studies have shown that in vitro models established as 3D spheroid cultures better reflect the biological and cellular characteristics of the same cells in vivo than standard 2D monolayer cultures (30, 40) ; therefore, we established these cell lines in 3D and suggest that they are robust representations of early-stage EOC development. This is supported by the similarities we observed for POE cells from different patients, in the phenotypic, morphological and molecular characteristics of the different genetic models. IOE CMYC.KRAS/BRAF cells had higher proliferative indices than IOE cells (measured by nuclear MIB1 staining), and when cultured in 3D exhibited features that were not present in 2D monolayer cultures (e.g. syncitial cell structures, pleiomorphic cellular shape and irregular nuclear morphologies). Prominent nucleoli were also visible, which have been shown to be a marker of MYCN amplifications in tumours (41) . Finally, unsupervised clustering based on gene expression data showed that any differences there may be in genetic background or clonal variation between POE cells from different patients were not strong enough to mask the effects of the individual or combined genetic elements that we manipulated in POE cells.
Transcriptomic analyses identified several novel candidate genes that were associated with neoplastic transformation after expressing CMYC and KRAS G12V or BRAF V600E in IOE cells. We followed up three genes (RGS4, CTGF and THBS1) that were significantly downregulated in transformed cells and for both IOE11 and IOE19 cell line models. For all three genes, expression analysis confirmed that they were down-regulated in ovarian cancer cell lines compared with POE cell lines, and in primary tumours compared with normal tissues. For these genes, there is already evidence from other studies implicating them EOC development. RGS4 (regulator of G-protein signalling 4) is involved in the regulation of signal transduction by G-protein coupled receptors and acts as a guanosine triphosphatase-activating protein (42) . Previous studies have found that loss of RGS4 expression is observed in EOC cell lines relative to IOE lines (43) . Loss of RGS4 is also associated with invasion and migration of breast and pancreatic cancer cells in vitro and in vivo (44, 45) . Reduced expression of CTGF (connective tissue growth factor), a secreted factor, may enhance the invasiveness of EOC cell lines in vitro (46) and is known to be involved in regulation of tumour-stroma interactions through transforming growth factor-b signalling (47) . The THBS1 (thrombospondin 1) gene encodes a subunit of an extracellular homotrimeric glycoprotein involved in cell-cell and cell-matrix interactions. THBS1 has been shown to inhibit angiogenesis in ovarian carcinomas and also pancreatic renal cell cancers (48) (49) (50) . Loss of THBS1 expression in several tumours types including EOCs is associated with enhanced tumour vasculature and poorer patient survival (50, 51) . Detailed in vitro and in vivo analyses will be required to fully evaluate the mechanisms by which mutations in these genes promotes transformation of IOE cells.
When we compared expression signatures derived for each oncogene model with expression profiles of primary EOCs from previously published data, we found a strong correlation between the signatures of IOE CMYC cells and high-grade (but not low malignant potential or LMP) EOCs. There is some debate about whether LMPs can develop into malignant tumours; this result may reflect the critical role of CMYC in the development of invasive EOCs rather then suggesting that CMYC alterations are late stage events in EOC development. Amplification at 8q24, which contains CMYC, occurs frequently in high-grade tumours (9) . More recently, common genetic variants at the 8q24 locus have been shown to confer lowpenetrance susceptibility to EOCs, perhaps suggesting CMYC alteration is tumour-initiating event (52) . We also found that BRAF expression signatures from our model correlated with the expression signatures of primary EOCs from patients with better relapse-free survival. This is consistent with the suggestion above that BRAF alterations are usually restricted to low-grade serous EOCs, which are known to be associated with better prognosis (37) and provides further evidence that genetic heterogeneity can influences the underlying aetiology of EOCs.
In summary, we have established an in vitro genetic model of initiation and early-stage progression of EOCs based on the activation of three proto-oncogenes (CMYC, KRAS and BRAF) that are known to be activated during the development of primary EOCs. Molecular and phenotypic analysis of the model suggests many characteristics that are consistent with the serous subtype of EOC. Transcriptomic profiling was used to validate the model by identifying both candidate genes and gene expression signatures that are features of primary EOCs, and molecular profiles that correlate with relapse-free survival in patients diagnosed with EOC. The similarities of this model to primary EOCs suggests it may have several clinical utilities including identifying novel biomarkers to screen for early-stage EOCS, predicting outcome and tailoring treatment in patients with EOC and identifying novel susceptibility markers or therapeutic targets for EOC. However, since ovarian cancers originate from heterogeneous normal epithelial cell precursors-fallopian tube epithelial cells, endometrial epithelial cells as well as POE cells (53), we suggest that parallel models of neoplastic transformation of each cell type, using subtype-relevant genetic alterations, will ultimately be required to fully characterize the initiating steps of ovarian cancer genesis. 
